Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant—a systematic review

Author:

Puyade Mathieu12ORCID,Maltez Nancy3,Lansiaux Pauline45,Pugnet Grégory67,Roblot Pascal18,Colmegna Ines910,Hudson Marie1011,Farge Dominique4510

Affiliation:

1. Centre Hospitalier Universitaire de Poitiers, Service de Médecine Interne, Maladies infectieuses, France

2. Centre Hospitalier Universitaire de Poitiers, CIC1402, Poitiers, France

3. Ottawa Hospital, Ottawa, Canada

4. Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France, AP-HP, Hôpital St-Louis, Saint Louis

5. Université de Paris, IRSL, Recherche clinique appliquée à l'hématologie, EA 3518, F-75010 Paris

6. CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, France

7. CHU de Toulouse, CIC 1436 module Biothérapie, Toulouse, France

8. Université de Poitiers, Poitiers, France

9. Research Institute of the McGill University Health Center, Montreal, Canada

10. Department of Medicine, McGill University, Montreal, Canada

11. Jewish General Hospital, Lady Davis Institute, Montreal, Canada

Abstract

Abstract Objectives In severe rapidly progressive SSc, autologous haematopoietic stem cell transplantation (AHSCT) allows significant improvements in overall and event-free survival. We undertook this study to identify, appraise and synthesize the evidence on health-related quality of life (HRQoL) before and after AHSCT for SSc. Methods We performed a systematic review of the literature, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, in PubMed and ScienceDirect from database inception to 1 February 2019. All articles with original HRQoL data were selected. Results The search identified 1080 articles, of which 8 were selected: 3 unblinded randomized controlled trials [American Scleroderma Stem Cell versus Immune Suppression Trial (ASSIST), Autologous Stem Cell Transplantation International Scleroderma, Scleroderma: Cyclophosphamide or Transplantation), 3 uncontrolled phase I or II trials and 2 cohort studies. HRQoL data from 289 SSc patients treated with AHSCT and 125 treated with intravenous CYC as a comparator with median 1.25–4.5 years follow-up were included. HRQoL was evaluated with the HAQ Disability Index (HAQ-DI; 275 patients), the 36-item Short Form Health Survey (SF-36; 249 patients) and the European Quality of Life 5-Dimensions questionnaire (EQ-5D; 138 patients). The quality of the studies was moderate to low. AHSCT was associated with significant improvement in the HAQ-DI (P = 0.02–<0.001), SF-36 Physical Component Summary score (P = 0.02–<0.0001) and EQ-5D index-based utility score (P < 0.001). The SF-36 Mental Component Summary score improved in the ASSIST (n = 19) and one small retrospective cohort (n = 30 patients, P = 0.005) but did not improve significantly in 2 randomized controlled trials (n = 200 patients, P = 0.1–0.91). Conclusion AHSCT in severe SSc patients is associated with significant and durable improvement in physical HRQoL.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Reference43 articles.

1. Systemic sclerosis;Denton;Lancet,2017

2. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres;Fransen;Ann Rheum Dis,2011

3. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies;Elhai;Rheumatology,2012

4. Clinical correlates of self-reported physical health status in systemic sclerosis;Hudson;J Rheumatol,2009

5. An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database;Brand;Clin Exp Rheumatol,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3